Furmonertinib Clinical Trials
12 recruitingDrug
Phase 210Phase 12Phase 31
Showing 1–12 of 12 trials
Recruiting
Phase 2
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
Tianjin Medical University Cancer Institute and Hospital30 enrolled3 locationsNCT07304739
Recruiting
Phase 1Phase 2
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Advanced Lung Cancer
Minghui Pharmaceutical (Hangzhou) Ltd300 enrolled1 locationNCT07229599
Recruiting
Phase 1Phase 2
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
NSCLC
InxMed (Shanghai) Co., Ltd.110 enrolled1 locationNCT05994131
Recruiting
Phase 3
Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
Advanced or Metastatic Non-small Cell Lung Cancer
Peking Union Medical College Hospital144 enrolled1 locationNCT06674343
Recruiting
Phase 2
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
Hunan Province Tumor Hospital40 enrolled1 locationNCT05379803
Recruiting
Phase 2
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
Changhai Hospital84 enrolled1 locationNCT06394674
Recruiting
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
CNS MetastasesEGF-R Positive Non-Small Cell Lung Cancer
Tang-Du Hospital30 enrolled1 locationNCT06352502
Recruiting
Phase 2
A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis
NSCLC
Jiangsu Province Nanjing Brain Hospital30 enrolled1 locationNCT06339242
Recruiting
Phase 2
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Juan LI, MD20 enrolled1 locationNCT06192849
Recruiting
Phase 2
Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Peking Union Medical College Hospital114 enrolled1 locationNCT05445310
Recruiting
Phase 2
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Non-small Cell Lung Cancer
Sun Yat-sen University280 enrolled26 locationsNCT05334277
Recruiting
Phase 2
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
Lung Adenocarcinoma Stage IIILung Adenocarcinoma Stage IVEGFR Gene Mutation
Shanghai Pulmonary Hospital, Shanghai, China96 enrolled1 locationNCT05503667